Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems

Figures & data

Table 1 Cost Inputs

Big 4/FSS Price Date	Ona 50U^a	Inco 50U	Ona 100U	Inco 100U	Ona 200U	Inco 200U^b
7/1/2014	N/A	$156.34	$395.47	$285.16	$779.67	N/A
7/1/2015	N/A	$156.47	$397.90	$288.47	$771.04	N/A
7/1/2016	N/A	$149.91	$397.83	$275.62	$754.39	N/A
7/1/2017	N/A	$152.10	$417.17	$279.65	$822.17	$697.35
7/1/2018	N/A	$155.48	$428.64	$285.87	$858.71	$707.65
7/1/2019	N/A	$155.48	$449.90	$285.87	$899.87	$571.74

Notes: Ona, onabotulinumtoxinA; Inco, incobotulinumtoxinA; a = onabotulinumtoxinA is not available as a 50 Unit vial; b = incobotulinumtoxinA was not available as a 200 Unit vial during the entire study period.

Figure 1 Nationwide VA/DoD incobotulinumtoxinA versus onabotulinumtoxinA total costs.

Notes: This figure reports the study’s primary outcome, which was the difference in total direct costs nationally for incobotulinumtoxinA (real-world) versus having hypothetically utilized onabotulinumtoxinA (projected) for similar utilization.

Figure 2 IncobotulinumtoxinA versus onabotulinumtoxinA cost outcomes at an anonymized institution.